Indonesia Again Receives COVID-19 Vaccine Support From Covax, This Time The Number Is Over 3 Million
JAKARTA - Indonesia through the COVID-19 Vaccine Global Access (Covax) facility has received back the arrival of the COVID-19 vaccine in two stages of arrival, namely the 155th and 156th to meet the national vaccination needs. The amount goes to the Government of the United States and other friendly countries who help in the availability of vaccines in Indonesia," said Vaccination Spokesperson from the Ministry of Health, Siti Nadia Tarmizi in a written statement received in Jakarta, reported by Antara, Sunday, December 12. The Covax facility is a joint program. to support access to COVID-19 prevention through collaboration to accelerate research, production and equal access to the COVID-19 vaccine. In the 155th stage of arrival, AstraZeneca vaccine arrived, totaling 1,749,600 doses on Saturday, December 11 at 21:59 WIB. The 156th phase is in the form of Pfizer vaccine, totaling 1,766,700 doses on Sunday, December 12 at 3:45 p.m WIB and 22.15 WIB.
The Indonesian government continues to make efforts to bring in a COVID-19 vaccine while accelerating and expanding the implementation of COVID-19 vaccination.
In addition to trying to vaccinate COVID-19 to remote, inland, and outermost areas, the scope of targeted vaccinations will also be expanded in the near future. The vaccination program for children 6-11 years old will start immediately in December 2021. This will further protect our children from the threat of COVID-19, including in carrying out limited face-to-face learning," said Nadia. Regarding the booster vaccine, Nadia said that the government is currently preparing according to priority groups, namely for health workers and the elderly (elderly). ), including those with a history of disease or comorbidities. According to him, it is important for the elderly to receive a booster because the ratio of COVID-19 cases in Indonesia's elderly is still high. The Ministry of Health will use available vaccine stocks, such as Sinovac, Sinopharm, Astrazeneca, Pfizer, and Moderna which has obtained a permit from the Food and Drug Supervisory Agency (BPOM) in Indonesia.